Baseline observations from the POSSIBLE EU® study: characteristics of postmenopausal women receiving bone loss medications

Freemantle, N., Cooper, C., Roux, C., Díez-Pérez, A., Guillemin, F., Jonsson, B., Ortolani, S., Pfeilschifter, J., Horne, R., Kakad, S., Shepherd, S., Möller, G., Marciniak, A. and Martinez, L. (2010) Baseline observations from the POSSIBLE EU® study: characteristics of postmenopausal women receiving bone loss medications. Archives of Osteoporosis, 5 (1-2). p. 61. 10.1007/s11657-010-0035-7.

Full text available as:

[img]
Preview
PDF (SPRINGER NESLI 2 LICENCE) - Published Version
261Kb

DOI: 10.1007/s11657-010-0035-7

Abstract

Prospective Observational Scientific Study Investigating Bone Loss Experience in Europe (POSSIBLE EU®) is an ongoing longitudinal cohort study that utilises physician- and patient-reported measures to describe the characteristics and management of postmenopausal women on bone loss therapies. We report the study design and baseline characteristics of 3,402 women recruited from general practice across five European countries. Purpose The POSSIBLE EU® is a study describing the characteristics and management of postmenopausal women receiving bone loss medications. Methods Between 2005 and 2008, general practitioners enrolled postmenopausal women initiating, switching or continuing treatment with bone loss treatment in France, Germany, Italy, Spain and the UK. Patients and physicians completed questionnaires at study entry and at 3-month intervals, for 1 year. Results Of 3,402 women enrolled (mean age 68.2 years [SD] 9.83), 96% were diagnosed with low bone mass; 55% of these using dual energy X-ray absorptiometry. Most women (92%) had comorbidities. Mean minimum T score (hip or spine) at diagnosis was −2.7 (SD 0.89; median −2.7 [interquartile range, −3.2, −2.2]) indicating low bone mineral density. Almost 40% of the women had prior fractures in adulthood, mostly non-vertebral, non-hip in nature, 30% of whom had at least two fractures and more than half experienced moderate/severe pain or fatigue. Bisphosphonates were the most common type of bone loss treatment prescribed in the 12 months preceding the study. Conclusions POSSIBLE EU® characterises postmenopausal women with low bone mass, exhibiting a high rate of prevalent fracture, substantial bone fragility and overall comorbidity burden. Clinical strategies for managing osteoporosis in this population varied across the five participating European countries, reflecting their different guidelines, regulations and standards of care.

Item Type:Article
Uncontrolled Keywords:Cohort studies – Osteoporosis – Postmenopausal osteoporosis – Prospective studies
Departments, units and centres:Department of Practice and Policy > Centre for Behavioural Medicine
ID Code:2159
Journal or Publication Title:Archives of Osteoporosis
Deposited By:Library Staff
Deposited On:10 Jun 2011 09:14
Last Modified:10 Jun 2011 09:14

Repository Staff Only: Item control page

School of Pharmacy Staff Only: Edit a copy to replace this item